DNA interaction, antioxidant activity, and bioactivity studies of two ruthenium(II) complexes

Insights into the in vitro Anticancer Effects of Diruthenium‐1

“…[32] The antiproliferativea ctivity of DiRu-1 and its cytotoxic effects on the MCF-7c ell line in our study are also much highert han those reported for considerably longert reatment (72-96 h) of this cell line with NAMI-A (IC 50 = 594.2-619.8 mm) [31,33] or cisplatin (IC 50 = 2-35.2 mm). [28,[30][31][32] In comparison with our previousr esults with A2780 and A2780cisR cells, [19] DiRu-1 displays similar, highero r lower cytotoxicity than other cationic dinuclear p-cymene ruthenium trithiophenolato complexes (depending on their structure), but shows considerably higherc ytotoxicity than cisplatin.…”

“…For instance, micromolar IC 50 values have been estimated for MCF‐7 cells incubated for 48 h with ruthenium(II) complexes [Ru(dmp) 2 (NHPIP)](ClO 4 ) 2 (dmp=2,9‐dimethyl‐1,10‐phenanthroline) and [Ru(dmp) 2 (AHPIP)](ClO 4 ) 2 , containing polypyridyl ligands with nitro, amino, or hydroxy groups (IC 50 : 5.1 to 18.5 μ m , respectively) . A broad range of IC 50 values (3.3–778.3 μ m ) were reported for MCF‐7 cells incubated for 48–96 h with Ru II polypyridyl complexes [Ru(bpy) 2 (N‐N)]Cl 2 , containing aromatic bidentate ligands (N‐N=bpy, phen, dpq, dppz, and dppn), mixed‐ligand ruthenium polypyridyl complexes with phenanthroline derivatives of varying lipophilicities (17.8–134.2 μ m ), ruthenium complexes containing EGFR‐inhibiting 4‐anilinoquinazoline pharmacophores (54–88 μ m ), and ruthenium complexes with dcdppz (15.2–22.5 μ m ) or β‐carboline alkaloid (5.9–260.3 μ m ) as ligands . Some ruthenium polypyridyl complexes such as [(η 6 ‐C 6 Me 6 )Ru(L)Cl](CF 3 SO 3 ) (L=dpq, dppz, and dppn) were found to exhibit higher cytotoxicity against the MCF‐7 cell line (IC 50 =0.13–11.1 μ m ), but the cells were exposed to the ruthenium complexes for a significantly longer time period (96 h) .…”

“…Some ruthenium polypyridyl complexes such as [(η 6 ‐C 6 Me 6 )Ru(L)Cl](CF 3 SO 3 ) (L=dpq, dppz, and dppn) were found to exhibit higher cytotoxicity against the MCF‐7 cell line (IC 50 =0.13–11.1 μ m ), but the cells were exposed to the ruthenium complexes for a significantly longer time period (96 h) . The antiproliferative activity of DiRu‐1 and its cytotoxic effects on the MCF‐7 cell line in our study are also much higher than those reported for considerably longer treatment (72–96 h) of this cell line with NAMI‐A (IC 50 =594.2–619.8 μ m ) or cisplatin (IC 50 =2–35.2 μ m ) . In comparison with our previous results with A2780 and A2780cisR cells, DiRu‐1 displays similar, higher or lower cytotoxicity than other cationic dinuclear p ‐cymene ruthenium trithiophenolato complexes (depending on their structure), but shows considerably higher cytotoxicity than cisplatin.…”

Synthesis, Dna Binding, Anticancer and Cytotoxic Evaluation of Novel Ruthenium(ii) Isatin Based Schiff Base Complex

“…[23][24][25] Though there is a red-shift and hypochromism observed for the complex, which is lower than those observed for classical intercalators like ethidium bromide, which indicates that the binding of drug with DNA is purely electrostatic. The quantitative comparison of the DNA binding affinity of the complex, the intrinsic binding constants Kb of the complexes for binding with CT DNA were evaluated by using equation (1). 26 [ DNA ] / ( εA − εf…”

“…Chelating compounds have been used to probe DNA as agents for mediation of strand scission of duplex DNA and as chemotherapeutic agents. [1][2][3][4][5][6][7] Metal chelates of 1,10-phenanthroline (phen) or modified phenanthroline ligands are particularly attractive for developing a new class of therapeutic agents that can cleave DNA. [8][9][10][11][12][13][14] Ruthenium complexes having phenanthroline/bipyridyl along with other co-ligands such as hydride, halides and CO have been studied extensively.…”